Halozyme Therapeutics: Royalty King
Halozyme Therapeutics is experiencing significant growth in shareholder value, primarily due to strong royalty performance and careful capital management. The company reported better-than-expected Q1 2026 earnings and has set ambitious guidance for the next few years. Additionally, Halozyme announced a substantial share repurchase program while trading at a discount compared to historical and sector valuations.
- ▪Halozyme Therapeutics reported a double beat on Q1 2026 earnings.
- ▪The company reaffirmed its guidance for 2026 to 2028.
- ▪Halozyme announced a new $1 billion share repurchase program.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906816-halozyme-therapeutics-royalty-king"},"author":{"@type":"Person","name":"Thomas…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
